|
We are committed to the development of novel therapies to increase lifespan and improve the quality of life by reducing the risk, prevalence, and impact of diabetes and obesity. Areas of Interest Oral diabetes segment - Insulin sensitisers - Glucose dependent insulin secretagogues (oral GLP-1, PTP-1b) - Beta cell protection/regeneration - Compounds should have beneficial or neutral effect on other CV risk factors, including body weight Step-change insulins and management - Non-injectable administration (oral, inhalation or transdermal) - Non-invasive glucose monitoring Injectable diabetes segment - Beta cell protection/regeneration - Glycaemic control and weight loss - Best in Class GLP-1 agonists Obesity - Novel mechanism for weight loss/prevention of weight gain including appetite and/or energy expenditure - Early stage opportunities with proof of concept in preclinical models - Good safety profile |
